Cancer Trials Should Focus On Collecting Data ‘Strictly Necessary’ For Assessing Efficacy
Executive Summary
In journal article, leaders from academia, industry, NCI and FDA propose building upon pandemic-necessitated flexibilities in clinical research, including making it easier for trial participants to access investigational drugs in their own communities and reduced reporting of uninformative adverse events.